A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Unlike type 1, type 2 diabetes can sometimes be prevented. According to the charity Diabetes UK, research has shown for some ...

The FDA has accepted Regeneron Pharmaceuticals’ sBLA for Eylea HD (aflibercept) injection 8mg for priority review.

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

Diabetic retinopathy (DR), a serious eye condition caused by damage to the blood vessels in the retina—the light-sensitive tissue at the back of the eye—is a ma ...

Eyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy ...

BOSTON – Boston Celtics coach Joe Mazzulla on Sunday confirmed a report that Jaylen Brown received injections during the week to help his troublesome right knee that’s limited his playing time ...